Li CY, Chen LC, Lin HY, et al. - Researchers investigated the effectiveness of the 23‐valent pneumococcal polysaccharide vaccine (PPSV23) in patients with prostate cancer who are at risk of pneumonia because of age and cancer treatments, including androgen‐deprivation therapy. Out of 38,735 patients with prostate cancer who were diagnosed between 2000 and 2010, they recruited 2,188 vaccinated patients and 2188 unvaccinated patients. Outcomes suggest that vaccination with the relatively common and inexpensive PPSV23 can reduce the risk of pneumonia among elderly patients who have prostate cancer and prolong their survival. Patients who got the PPSV23 had a significantly reduced incidence density, with 142.8 per 1,000 person‐years vs 162.0 per 1,000 person‐years for unvaccinated patients, over 7 years of follow‐up. Patients who got the PPSV23 vaccine had a lower cumulative incidence for the first occurrence of pneumonia‐related hospitalization and higher overall survival vs unvaccinated controls.